Registration Number
0224U033470,
(0121U112052)
, R & D reports
Title
Development of the individual approaches to antiblastomic therapy in patients recovered from COVID-19.
popup.stage_title
Розроблення алгоритмів антибластомного лікування у пацієнтів, які перенесли COVID-19, шляхом індивідуалізації спеціального лікування та профілактичної терапії.
Head
Krasnoselskyi Mykola V., Доктор медичних наук
Starenkyi Viktor P., Доктор медичних наук
Registration Date
28-12-2024
Organization
State Organization "Grigoriev Institute for Medical Radiologiy and Oncology of the National Academy of Medical Sciences of Ukraine"
popup.description1
To determine the indications and optimal conditions for antiblastomic therapy in patients recovered from COVID-19 by individualizing terms, treatment regimens and supportive care considering clinical and laboratory characteristics.
popup.description2
Object of study: oncology patients who have experienced COVID-19. Research objective: determine the indications and optimal conditions for carrying out antiblastoma therapy in patients who have suffered from COVID-19, by individualizing the terms, treatment regimens and accompanying therapy, taking into account clinical and laboratory characteristics. Methods and apparatus: clinical-instrumental, immunological, hematological, Respons 910 biochemical photoelectric automatic analyzer, SUNRISE TECAN microplate photometer, XN-L550 automatic hematological analyzer. Theoretical and practical results use of the developed algorithms does not reduce the overall effectiveness of treatment and does not increase the frequency of grade 3 complications due to the individualization of treatment regimens and concomitant therapy. The practical result is the technology for planning antiblastoma treatment of patients with stage III-IV laryngeal cancer and the technology for assessing antitumor immunoreactivity in patients who have had COVID-19. An algorithm for antiblastoma treatment of patients with squamous cell carcinoma of the head and neck, rectal cancer, breast cancer, cervical cancer and uterine corpus cancer who have had COVID-19 has been developed, which makes it possible to conduct a full course of therapy without dose reduction and shortening the duration of treatment, as well as to separate patients who need additional concomitant therapy. Novelty: algorithms for the treatment of cancer patients who have had COVID-19 have been developed, taking into account post-COVID complications, assessing the state of all body systems according to the ECOG scale and the stage of the disease. The effectiveness of implementation: technology makes it possible to maintain the clinical efficacy of antiblastoma treatment and reduce grade 3 complications in cancer patients with severe post-COVID syndrome by 20%. Field of use: oncology, medical radiology.
Product Description
popup.authors
Ivanenko Maryna O.
Izotov Serhii V.
Artamonova Neonila O.
Artiukh Serhii V.
Bilyi Oleksandr M.
Bilozor Nataliia V.
Bobrova Vladyslava M.
Vasyliev Leonid L.
Havrylenko Mykyta V.
Hladkykh Fedir V.
Hradil Hryhorii I.
Hromakova Iryna A.
Zakrutko Anna O.
Kantsedal Olena M.
Kolomatska Viktoriia V.
Kolpak Kseniia O.
Kosheleva Iryna V.
Kuzmenko Olena V.
Kulinich Halyna V.
Lukashkova Olha P.
Maistrenko Ihor O.
Niemykina Nadiia V.
Nasonova Alla M.
Pidlisnyi Ruslan A.
Pshyshevska Liudmyla A.
Radzishevska Yevheniia B.
Simonova-Pushkar Larysa I.
Samofalov Ihor O.
Sviatenko Nina I.
Slobodianiuk Olha V.
Sorochan Pavlo P.
Spuziak Roman M.
Sukhina Olena M.
Teslenko Iryna M.
popup.nrat_date
2024-12-28
